Compare AbbVie Inc (ABBV) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Southern Copper Corp — how do they compare? AbbVie Inc trades at $249.5 (market cap $438.19B), while Southern Copper Corp trades at $195 (market cap $166.96B). The key difference: AbbVie Inc is far larger — about 2.6× Southern Copper Corp's market cap, and AbbVie Inc pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| ABBV | SCCO | |
|---|---|---|
Market Cap | $438.19B | $166.96B |
Sector | Health | Basic Materials |
52-Week High | $263.58 | $218.85 |
52-Week Low | $197.38 | $93.70 |
Enterprise Value | $502.45B | $168.25B |
Dividend Yield | 2.79% | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
Southern Copper (SCCO) trades at $199.06, up 3.12% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $2.01 vs. $1.98, revenue growth from $13.42B in 2025 to projected $15.8B in 2026, and exceptional profitability with 35.87% net margin. Recent corporate actions include dividends and stock splits, while institutional activity shows increased positions from Dimensional Fund Advisors and CalPERS.
SCCO presents growth potential driven by strong earnings performance and AI-driven copper demand, but faces risks from analyst skepticism (41.38% sell ratings) and valuation concerns with P/E of 29.51. The stock trades above consensus price target of $153.64, suggesting limited near-term upside despite positive technical momentum and fundamental strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
